AHCYL2

Across TCGA pan-cancer cohorts, AHCYL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AHCYL2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AHCYL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AHCYL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and COAD are the cancer types where AHCYL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.507	0.253	<.001	47	view →
HNSC	DFS	Tertile	III,IV	1.000	0.861	.005	25	view →
COAD	DFS	Median	III,IV	1.000	0.835	.032	18	view →
GBM	OS	Quartile	All	0.713	0.438	.036	4	view →
LSCC	OS	Median	All	0.871	0.746	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AHCYL2–PDAC (DFS)

Open the PDAC breakdown →